Amgen completes Onyx merger
Amgen has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals for $125 per share in cash. As announced Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash.
Approximately 57,698,132 shares were validly tendered and not withdrawn in the tender offer, representing approximately 78.5% of Onyx's outstanding shares. Amgen has accepted for payment and will pay for all validly tendered shares.
All remaining eligible Onyx shares will be converted into the right to receive $125 per share in cash, without interest and less any applicable withholding taxes, the same price paid in the tender offer.